Recent data on ADL in CF patients treated with ELX/TEZ/IVA have been very limited, because these patients are excluded from many studies, due to the adverse events and the unimportant lung function improvements noticed with previous CFTR modulators. Here, CFTR is linked to cystic fibrosis.